BCL2 and MYC Dual-Hit Lymphoma/Leukemia
スポンサーリンク
概要
- 論文の詳細を見る
Translocation of the BCL2 gene on the chromosome band 18q21.3 results in consistent expression of the Bcl2 protein, an apoptosis inhibitor. BCL2 usually translocates to the immunoglobulin (IG) heavy chain (IGH) gene as t(14;18)(q32;q21.3) and rarely to IG light chain (IGK, IGL) loci as t(2;18)(p11;q21.3) or t(18;22)(q21.3;q11). The t(14;18) translocation is observed in 70-95% of follicular lymphoma cases and 20-30% of diffuse large B-cell lymphoma (DLBCL) cases. The MYC gene on chromosome band 8q24 acts as an accelerator of cell proliferation. MYC translocates to 14q32/IGH as t(8;14)(q24;q32) or less commonly to 2p11/IGK as t(2;8)(p11;q24) or 22q11/IGL as t(8;22)(q24;q11). The 8q24/MYC translocation is detected in nearly all Burkitt lymphoma (BL) and up to 10% of DLBCL cases. Both translocations rarely occur in an identical cell and this lymphoid malignancy is termed BCL2 and MYC dual-hit lymphoma/leukemia (DHL). The pathological diagnosis in most cases of DHL with BCL2-IG and MYC-IG translocation is B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and BL, although DLBCL is most common in DHL with BCL2-IG and MYC-nonIG translocation. The frequency of DHL with BCL2 and MYC translocation is estimated at around 2% of all B-cell malignancies. The condition is characterized by elevated serum lactate dehydrogenase levels, the presence of B symptoms, bone marrow involvement, advanced disease stage, extranodal involvement, and central nervous system (CNS) involvement at presentation or disease progression. Despite treatment strategies including CNS-targeted therapy, the prognosis for DHL is extremely poor. In this review, the current knowledge of the clinicopathological status of DHL is summarized and discussed. [J Clin Exp Hematopathol 51(1) : 7-12, 2011]
- 2011-05-01
著者
-
Tomita Naoto
Department Of Hematology Graduate School Of Medicine Yokohama City University
-
Tomita Naoto
Department Of Internal Medicine And Clinical Immunology Yokohama City University Graduate School Of
関連論文
- Outcome of Involved-Field Radiotherapy for Stage 1 Follicular Lymphoma
- Prognostic Factors in Diffuse Large Bcell Lymphoma Treated by Riskadopted Therapy
- Serum HO-1 is useful to make differential diagnosis of secondary hemophagocytic syndrome from other similar hematological conditions
- Expression of heme oxygenase-1 in human leukemic cells and its regulation by transcriptional repressor Bach1
- Secondary Central Nervous System Lymphoma
- Aberrant CD20 Expression in Angioimmunoblastic T-cell Lymphoma
- Primary Hepatic Peripheral T-Cell Lymphoma Treated with Corticosteroid
- F-18 FDG PET/CT evaluation of radiotherapy response in rare case of mucosa-associated lymphoid tissue lymphoma
- BCL2 and MYC Dual-Hit Lymphoma/Leukemia
- Pretransplant serum ferritin is associated with bloodstream infections within 100 days of allogeneic stem cell transplantation for myeloid malignancies
- Retrospective Study of the Utility of FLIPI/FLIPI-2 for Follicular Lymphoma Patients Treated with R-CHOP
- Prognostic factors in patients aged 50 years or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancy
- Phase II study of CHOP-GR therapy in diffuse large B-cell lymphoma
- Standard R-CHOP Therapy in Follicular Lymphoma and Diffuse Large B-Cell Lymphoma
- The 3q27 and 18q21 Translocations for Follicular Lymphoma and Diffuse Large B-Cell Lymphoma in the Rituximab Era
- Successful treatment of a pregnant woman with Philadelphia chromosome-positive acute lymphoblastic leukemia